Description

Zonisamide USP

Zonisamide USP is a high-purity, sulfonamide-derived anticonvulsant used in pharmaceutical formulations for the treatment of partial seizures and as adjunctive therapy in epilepsy management. Compliant with United States Pharmacopeia (USP) standards, it exhibits multiple mechanisms of action, including blockade of voltage-gated sodium and T-type calcium channels, resulting in the stabilization of neuronal membranes and suppression of abnormal electrical activity in the brain. Zonisamide
• Is a USP-compliant anticonvulsant for oral dosage forms
• Is used in the treatment of partial-onset seizures and other neurological disorders
• Acts by inhibiting sodium and calcium channel activity and modulating neurotransmission
• Is suitable for tablets, capsules, and controlled-release formulations
• Is manufactured under Good Manufacturing Practice (GMP) certified conditions
• Is supplied with complete regulatory documentation including Certificate of Analysis (CoA) and technical data
Zonisamide USP is chemically designated as 1,2-Benzisoxazole-3-methanesulfonamide. It appears as a white to off-white crystalline powder, slightly soluble in water, freely soluble in dimethylformamide and ethanol, and stable under standard storage conditions.
In pharmaceutical applications, Zonisamide USP is used in:
• Oral capsules and tablets for the treatment of partial-onset seizures
• Adjunctive therapy in patients with refractory epilepsy
• Combination treatments in neurological and neuroprotective formulations
• Clinical research focused on anticonvulsant and neuroregulatory mechanisms
• Compounded preparations requiring controlled bioavailability and stability
Zonisamide USP provides broad-spectrum anticonvulsant activity, demonstrating both sodium channel blockade and modulation of dopaminergic and serotonergic pathways. It has a long elimination half-life, supporting once-daily dosing and improved patient compliance.
CarboMer supplies Zonisamide USP that is characterized by assay, polymorphic form, residual solvents, and microbial content. The material meets USP monograph specifications and is suitable for regulated pharmaceutical manufacturing.
The material is packaged in sealed, moisture-resistant, tamper-evident containers. It is available in laboratory, pilot, and commercial-scale volumes. Minimum order quantities (MOQ), lead times, and documentation including CoA and SDS are provided upon request.
Each batch is tested for identity (IR, HPLC), assay (anhydrous basis), water content, residual solvents, heavy metals, and microbial limits. Certificates of Analysis (CoA), Safety Data Sheets (SDS), and full traceability documentation accompany every shipment.
As with all CarboMer central nervous system APIs, Zonisamide USP is supported by formulation expertise, regulatory compliance assistance, and a dependable global supply chain to ensure safe, effective, and high-quality pharmaceutical product performance.